RYAH Group Inc. Offers IoT Suite of Products Disrupting Future of Medicine

April 9, 2021 13:30:10
  • Every product features three parts: dosing device, formulation accessory and mobile app
  • HIPPA-compliant cloud collects data along each step that is essential in tailoring personalized treatment plan
  • RYAH offers multi-product ecosystem that provides remote-health solutions in patient treatment

RYAH Group a digital health-care analytics and technology company, has developed an ecosystem of IoT products in its mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments (https://ibn.fm/1wvz4). Every product features three parts: the device, the formulation accessory (QR labeled product) and the mobile application. These parts work together to control the dosing while also capturing important data that can lead to breakthroughs in plant-based medicine.

Every RYAH dose-measuring product has an innovative dose-control solution. Using QR-labeled products, patients can track what they use and evaluate what dosing parameters work best for each product. The QR labeling allows for advanced session tracking and journaling and is designed to ensure safety. Patients can then control and rate the effectiveness of each session on RYAH’s mobile app. This allows the user to tweak future doses to provide more optimal results.

The HIPPA-compliant cloud collects data along each step of the ecosystem that is essential in tailoring a personalized treatment plan moving forward. The suite of products also provides critical information for future treatment of patients with various medical conditions. The company releases a monthly in-depth analytical report sharing publicly identified trends and how dosing affects consumer outcomes.

RYAH ecosystem includes a range of IoT devices, including Smart Patch, Smart Inhaler and the upcoming Smart Pen, as well as RYAH MD remote health platform.

The Smart Patch allows users to access on-demand relief and schedule doses based on when their symptoms are the most severe. After using the QR labeled product, the mobile app’s user records how well the patch worked. Users can then review stats and create an optimized schedule for later use. It creates an organized record of what patches worked best.

RYAH’s Smart Inhaler allows users to control how much is inhaled, ensuring consistent and predictable results. Temperature and dosage can be controlled, and then the effects can be recorded in the mobile app. Statistics can be reviewed, and dosing can be altered accordingly for future uses.

The Smart Pen allows for oral consumption and can uniquely dose up to three different liquid formulations for a highly personalized effect. The dose can be added to a drink or directly into the mouth. The app is then used to record the effects of the dose for review to make any changes for future dosing.

RYAH MD is a service that allows clinicians to remotely monitor and control patients’ dosing regimens with the before-mentioned dose-measuring products. It provides necessary information that doctors can analyze to learn how different dosing variables affect outcomes. RYAH MD allows the doctor to recommend parameters on the smart devices for dosing, review the information in real-time, and make changes remotely to the doses delivered. It will enable doctors to monitor their patients and ensure that they are following the recommended procedures.

RYAH Cloud captures all of the structured and unstructured data from the dosing products and the mobile apps and analyzes the information. This allows doctors and clinics to develop more personalized therapies that can reshape our medical future.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.